Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1

被引:590
作者
Shimada, T
Fujii-Kuriyama, Y
机构
[1] Osaka Prefectural Inst Publ Hlth, Higashinari Ku, Osaka 5370025, Japan
[2] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA
[4] Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan
关键词
D O I
10.1111/j.1349-7006.2004.tb03162.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitously distributed environmental chemicals. PAHs acquire carcinogenicity only after they have been activated by xenobiotic-metabolizing enzymes to highly reactive metabolites capable of attacking cellular DNA. Cytochrome P450 (CYP) enzymes are central to the metabolic activation of these PAHs to epoxide intermediates, which are converted with the aid of epoxide hydrolase to the ultimate carcinogens, diol-epoxides. Historically, CYP1A1 was believed to be the only enzyme that catalyzes activation of these procarcinogenic PAHs. However, recent studies have established that CYP1B1, a newly identified member of the CYP1 family, plays a very important role in the metabolic activation of PAHs. In CYP1B1 gene-knockout mice treated with 7,12-dimethylbenz[a]anthracene and dibenzo[a,l]pyrene, decreased rates of tumor formation were observed, when compared to wild-type mice. Significantly, gene expression of CYP1A1 and 1131 is induced by PAHs and polyhalogenated hydrocarbons such as 2,3,7,8-tetra-chlorodibenzo-p-dioxin through the arylhydrocarbon receptor. Differences in the susceptibility of individuals to the adverse action of PAHs may, in part, be due to differences in the levels of expression of CYP1A1 and 1131 and to genetic variations in the CYP1A1 and 181 genes.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 59 条
[51]  
Tang MS, 2000, CANCER RES, V60, P5688
[52]   Benzo[a]pyrene-induced toxicity:: Paradoxical protection in Cyp1a1(-/-) knockout mice having increased hepatic BaP-DNA adduct levels [J].
Uno, S ;
Dalton, TP ;
Shertzer, HG ;
Genter, MB ;
Warshawsky, D ;
Talaska, G ;
Nebert, DW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 289 (05) :1049-1056
[53]   INHIBITION OF THE BINDING OF 7,12-DIMETHYLBENZ[A]ANTHRACENE AND BENZO[A]PYRENE TO DNA IN MOUSE SKIN EPIDERMIS BY 1-ETHYNYLPYRENE [J].
VIAJE, A ;
LU, JYL ;
HOPKINS, NE ;
NETTIKUMARA, AN ;
DIGIOVANNI, J ;
ALWORTH, WL ;
SLAGA, TJ .
CARCINOGENESIS, 1990, 11 (07) :1139-1143
[54]   RAT CYP1B1 - AN ADRENAL CYTOCHROME-P450 THAT EXHIBITS SEX-DEPENDENT EXPRESSION IN LIVERS AND KIDNEYS OF TCDD-TREATED ANIMALS [J].
WALKER, NJ ;
GASTEL, JA ;
COSTA, LT ;
CLARK, GC ;
LUCIER, GW ;
SUTTER, TR .
CARCINOGENESIS, 1995, 16 (06) :1319-1327
[55]  
WARKER NJ, 1999, TOXICOL APPL PHARM, V154, P279
[56]   Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer [J].
Watanabe, J ;
Shimada, T ;
Gillam, EMJ ;
Ikuta, T ;
Suemasu, K ;
Higashi, Y ;
Gotoh, O ;
Kawajiri, K .
PHARMACOGENETICS, 2000, 10 (01) :25-33
[57]   CYTOCHROME P450 2E1 AND 2A6 ENZYMES AS MAJOR CATALYSTS FOR METABOLIC-ACTIVATION OF N-NITROSODIALKYLAMINES AND TOBACCO-RELATED NITROSAMINES IN HUMAN LIVER-MICROSOMES [J].
YAMAZAKI, H ;
INUI, Y ;
YUN, CH ;
GUENGERICH, FP ;
SHIMADA, T .
CARCINOGENESIS, 1992, 13 (10) :1789-1794
[59]   Characterization of the mouse Cyp1B1 gene -: Identification of an enhancer region that directs aryl hydrocarbon receptor-mediated constitutive and induced expression [J].
Zhang, LY ;
Savas, U ;
Alexander, DL ;
Jefcoate, CR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (09) :5174-5183